| NCT ID | NCT07591337 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin Medical University |
| Condition | Vascular Aging |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2026-05-01 |
| Primary Completion | 2029-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2026-05-01 with a primary completion date of 2029-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cardiovascular diseases pose a serious threat to public health, and their prevalence is on the rise year by year. Vascular aging is an independent risk factor for cardiovascular diseases, and endothelial cell senescence is an early event in vascular aging. Its occurrence can lead to endothelium-dependent vasodilation dysfunction, reduced vascular permeability, and the release of the senescence-associated secretory phenotype (SASP). These vascular pathological changes further damage the vascular media, leading to vascular remodeling and reduced compliance, accelerating the progression of atherosclerosis, and ultimately resulting in cardiovascular diseases such as coronary heart disease and hypertension. Recent research of the investigators has revealed that SNRK, a new member of the AMPK family of cellular energy sensors, plays a key regulatory role in vascular development. Based on this finding, the investigators propose the scientific hypothesis that SNRK responds to both physiological and pathological aging stimuli through differential mechanisms and regulates the process of endothelial cell senescence. In this study, the investigators will explore the correlation between SNRKAS and carotid vascular structure and endothelial function by measuring the levels of the SNRK upstream lncRNA (SNRKAS) in participants' peripheral blood, in conjunction with carotid ultrasound examinations. The findings will provide a solid scientific basis for elucidating new mechanisms underlying the onset and progression of vascular aging and for identifying novel therapeutic targets.
Eligibility Criteria
Inclusion Criteria: 1. Aged 18-80 years, with the capacity to make decisions independently or represented by an authorized legal guardian; 2. Able to provide complete personal information, medical history, and lifestyle history (e.g., smoking and alcohol consumption history); 3. No history of severe cardiovascular disease, and deemed eligible for inclusion by a physician. Exclusion Criteria: 1. Women who are pregnant or may become pregnant; 2. Patients with a history of neurological disorders, tumors, severe cardiovascular or pulmonary disease, liver failure, kidney failure, or blood disorders; 3. Patients who have undergone carotid stenting, carotid endarterectomy, or other similar procedures, or who have unilateral carotid artery occlusion due to any cause; 4. Patients who have participated in another clinical trial within the past 4 weeks; 5. Individuals deemed unsuitable for this clinical trial by the investigators.
Contact & Investigator
Minghui Zou, Ph.D.
STUDY CHAIR
mhzou@tmu.edu.cn
Frequently Asked Questions
Who can join the NCT07591337 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Vascular Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07591337 currently recruiting?
Yes, NCT07591337 is actively recruiting participants. Contact the research team at xge@tmu.edu.cn for enrollment information.
Where is the NCT07591337 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT07591337 clinical trial?
NCT07591337 is sponsored by Tianjin Medical University. The principal investigator is Minghui Zou, Ph.D. at mhzou@tmu.edu.cn. The trial plans to enroll 180 participants.